ASPG and neoplasm: Patients who do not express high levels of ASNS might benefit from being treated with recombinant L-asparaginase, since this treatment induces apoptosis in vitro, reduces GBM growth when tumour cells are implanted subcutaneously in mice and enhances ABT263 anti-tumoural effects (a BCL2/BCL-XL inhibitor) (Karpel-Massler et al., 2016).